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Understanding probiotic action may permit modulation of the
immune system, both locally and systemically
T
here is considerable public, media,
and scientific interest in ‘‘natural’’
products, including probiotics, in
modulating intestinal inflammation
and health.1 Intestinal microflora are
intimately involved in the generation of
immunocompetent cells and tuning the
balance between T helper 1 (Th1) and
Th2 immunity during the development
of the gut associated immune system.
It is now generally accepted that the
intestinal bacterial flora contributes
significantly to the pathogenesis of
inflammatory bowel disease (IBD) along
with mucosal immune dysregulation
and genetic susceptibility. Considerable
research is focused on modifying the
intestinal flora with probiotic bacteria
to attenuate inflammatory activity
and prevent relapses in ulcerative coli-
tis, Crohn’s disease, and pouchitis.
Although both Lactobacillus species and
Bifidobacterium species are frequently
used, the optimum use of probiotics in
IBD requires greater understanding of
their effects on the immune system.
A rationale for the use of probiotics in
IBD stems from reports of dysbiosis in
the intestinal flora in ulcerative colitis,
Crohn’s disease, and pouchitis, either by
conventional anaerobic culture or by
analysis using molecular probes. It is
however unclear whether such altera-
tions in intestinal flora drives the
inflammation or is a consequence of it.
The practical application of probiotic
strategy has been especially encouraged
by the positive results of a trial in its use
for the prevention and treatment of
pouchitis.2 3 The multispecies probiotics
used pose special challenges in identify-
ing precise mechanism of action,
although alterations in faecal flora have
been demonstrated.4 Despite some posi-
tive trials, generalisation from pouchitis
to their use for all forms of IBD appears
somewhat premature, however, as for
example, a trial of administration of
Lactobacillus GG after surgical resection
for Crohn’s disease proved ineffective in
preventing relapse.5 Further studies are
therefore required in ulcerative colitis
and Crohn’s disease before firm recom-
mendations may be made.
Lactobacilli are a major constituent of
the intestinal microflora and are fre-
quently used as probiotics, often in the
health food industry.6 Among the
Lactobacillus genus, different species of
bacteria induce distinct mucosal cyto-
kine profiles in the gut immune system
of BALB/c mice.7 For example, an
increase in the Th2 cytokines interleukin
(IL)-10 and IL-4 was observed in mice
fed Lactobacillus delbrueckii subspecies
Bulgaricus and Lactobacillus casei whereas,
in contrast, a significant induction of
the Th1 cytokines IL-2 and IL-12 was
observed with Lactobacillus acidophilus. It
is therefore important that notice is
taken of which specific bacteria are
being used.
Various knockout, transgenic, and
adoptive transfer murine and rodent
models of IBD have been generated
and the requirement for bacterial col-
onisation to induce a IBD phenotype is
virtually universal, despite the complex-
ities of the immune network.8 In con-
trast, in the IL-10 knockout mice model
of colitis, probiotic therapy with Lacto-
bacillus species and Bifidobacterium spe-
cies has been shown to be effective in
reducing inflammation.9 10 In animal
models, probiotic therapy may prevent
relapses of colitis, as shown by treat-
ment with Lactobacillus GG in HLA-B27
transgenic rats after antibiotic treat-
ment.11 It is therefore clear that not all
bacteria have the same actions on gut
immune function. Separating them into
‘‘good’’ and ‘‘bad’’ bacteria, a marketing
strategy often used in the commercial
industry, is however a gross oversimpli-
fication, and takes no account of host
differences as a contributory factor.
In this issue of the Gut, researchers
from Cork, Ireland,12 challenge the con-
ventional hypothesis of mechanisms
of probiotic efficacy by administering
Lactobacillus salivarius subcutaneously to
IL-10 knockout mice [see page 694].
The anti-inflammatory effect of subcu-
taneous administration was not specific
as it was also seen in a murine model of
arthritis. Non-viable bacteria could not
be tested as the group receiving heat
treated L salivarius had 100% mortality
by week 10. No change in faecal micro-
flora occurred as a result of this sub-
cutaneous administration of L salivarius,
suggesting a mechanism of action dis-
tinct from colonic floral modulation.
Various indicators of altered immune
function were seen with decreased
tumour necrosis factor (TNF) and
IL-12 levels being obtained from sple-
nocytes that had been stimulated by
Salmonella typhimurium. In contrast,
transforming growth factor (TGF)-b
levels were maintained. Such systemic
anti-inflammatory activity is counter-
intuitive to a simplistic model of gut
flora modulation, and leads to specula-
tion about the molecules involved in
driving immunomodulation.
The findings of the current study are
not the first to suggest that probiotics
have more than a local anti-inflamma-
tory effect by modulating the flora. For
example, Lactobacillus casei or Lacto-
bacillus bulgaricus reduced the inflamma-
tory response induced by coculture of
bacteria with mucosal explants from
Crohn’s disease affected intestinal tis-
sue. In this study, a significant reduc-
tion of proinflammatory cytokines such
as TNF was noted.13 Such anti-inflam-
matory effect might even be systemic,
as shown by the bacteria CpG DNA
experiments discussed later.
Probiotics may also influence mucosal
cell-cell interactions and cellular ‘‘stabi-
lity’’ by actions such as enhancement of
intestinal barrier function by modulat-
ing cytoskeletal and tight junctional
protein phosphorylation. For example,
live probiotics such as Lactobacillus acid-
ophilus or Streptococcus thermophilus pro-
tect in vitro intestinal epithelial cell
lines (HT29, Caco-2) from pathogen
invasion and adhesion by enteroinvasive
Escherichia coli.14 Similarly, the non-
pathogenic E coli strain Nissle 1917
inhibited adhesion and invasion of
intestinal epithelial cell line (intestine
407) by adherent invasive E coli strains
isolated from patients with Crohn’s
disease.15
In ‘‘the age of the genome’’, it is not
surprising that much time and atten-
tion has been spent on studying the
importance of the detailed bacterial
DNA sequences in these effects. Bac-
terial DNA contains non-methylated
CpG motifs which bind to toll-like
receptor 9 (TLR-9). TLR-9 signalling is
dependent on the adaptor protein
MyD88. Such immunostimulatory DNA
sequences (ISS-DNA or CpG DNA) of
bacterial origin have been shown to
reduce inflammation in rodent IBD
models such as DSS induced colitis,
hapten induced colitis in BALB/c mice,
and the IL-10 knockout mice model of
colitis. This reduction in inflamma-
tion was accompanied by inhibition of
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proinflammatory cytokine and chemo-
kine production and suppression of
induction of matrix metalloproteinases
in the colon.16
Further evidence of the central role
of bacterial DNA has come from novel
experiments where both intragastric
and subcutaneous administration of
probiotic and E coli DNA attenuated
the severity of DSS induced colitis.17 The
form that this DNA takes appears
crucial, as methylated probiotic DNA,
calf thymus DNA, and DNAse treated
probiotics were ineffective.
Given this complexity, do we need live
bacteria, dead bacteria, or just the DNA?
Unfortunately, the data are confusing
and sometimes contradictory. TLR-9 and
the adaptor protein MyD88 appear
essential in signalling, and in their
presence even non-viable bacteria can
signal. In TLR-9 deficient mice, unlike
TLR-2 or TLR-4 deficient mice, intragas-
tric c irradiated (that is, non-viable)
probiotics had no effect on DSS induced
colitis. Mice deficient in MyD88 did
not respond to c irradiated probiotics.17
The immune modulatory function of
DNA has also been demonstrated in a
study of peripheral blood mononu-
clear cells from healthy donors where
Bifidobacterium genomic DNA caused
induction of secretion of the anti-
inflammatory IL-10.18 Given the high
GC content of Bifidobacterium chromoso-
mal DNA, it will be of interest to assess
the effect of its subcutaneous adminis-
tration in the IL-10 knockout model of
colitis.
The immune modulatory properties
of the various probiotic bacteria may
differ, and this becomes problematic for
the use of multispecies preparations.
Furthermore, not all immunostimula-
tory oligonucleotides have the palindro-
mic CpG motif. In one study, chro-
mosomal DNA was purified from nine
strains of Lactobacillus delbrueckii sub-
species Bulgaricus and six strains of
Streptococcus thermophilus derived from
yoghurt starter cultures. Only DNA from
L bulgaricus NIAI B6 induced significant
proliferation of mice Peyer’s patch and
splenic B cells although it did not
contain a palindromic CpG motif.19 It is
therefore clear that ‘‘the devil is in the
detail’’ and extrapolation across DNA
sequences and bacterial species may
provide false impressions.
In addition to indirectly influencing
gut flora and stimulating immune res-
ponses, the probiotic strains themselves
produce antimicrobial peptides. Bac-
teriocin production is often associated
with probiotic strains, and Lactobacillus
salivarius cultures produce a broad spec-
trum bacteriocin that exhibits activity
against a range of microorganisms such
as Bacillus, Staphylococcus, Enterococcus,
and Listeria species. Bacteriocins are
synthesised in ribosomes as prepeptides
before being released extracellularly,
and their genetic locus in Lactobacillus
salivarius has been identified.20 Pro-
duction of different classes of bacterio-
cins confers a competitive survival
advantage in colonisation and therefore
these molecules are most relevant
within the intestinal flora, but their
systemic effects require further study.
Importantly, the production and activity
of bacteriocin is not affected by spray
drying which may facilitate commercial
preparation.21
There has recently been much interest
in the function of dendritic cells (DC)
in controlling gut immune activity. DC
act as the switch that determines the
delicate balance between Th1 and Th2
immunity, as well as tolerance (Th3).
Therefore, it is likely that the DC
phenotype and state of activation deter-
mine whether initiation of immunity or
tolerance takes place and DC are likely
to play a central role in mediating the
effect of probiotic bacteria and deter-
mining the type of immune response
that occurs. Different species of lacto-
bacillus exert different DC activation
patterns and the complexity of such
interactions is exemplified by demon-
stration that Lactobacillus reuteri, a poor
inducer of IL-12, is capable of inhibiting
DC activation by other Lactobacillus
species.22 The threshold of bacterial
concentration necessary to induce cyto-
kine production may be different for
proinflammatory cytokines IL-12/TNF
and anti-inflammatory/regulatory cyto-
kine IL-10, permitting fine modulation
of the immune response.22
Evidence of probiotic strains affecting
Th1/Th2 immune balance also comes
from experiments in which stimulation
of macrophages with Lactobacillus rham-
nosus GG induced mRNA expression of
the chemokines CCL2, CCL3, CCL5,
CCL7, CCL19, CCL20, CXCL8, CXCL9,
and CXCL10.23 Such a Th1 pattern of
chemokine induction could explain the
proposed antiallergenic properties of
this probiotic strain and may benefit
Th2 oriented ulcerative colitis. Interes-
tingly, studies of oral administration of
these bacteria suggest that they may
affect the systemic immune response.
For example, oral administration of
Lactobacillus rhamnosus GG to healthy
volunteers for five weeks affected the
systemic cellular immune response to
intestinal microorganisms.24
What about the host? Identification
of NOD2 mutations associated with
Crohn’s disease provides further support
for the central role of bacteria in the
pathogenesis.25 26 Three NOD2 muta-
tions located near or in the leucine rich
repeats involve a frameshift mutation
(Leu1007fsinsC) or two missense muta-
tions (Gly908Arg and Arg702Trp). These
alterations are associated with increased
risk of development of Crohn’s disease
and result in defective induction of
nuclear factor kB (NFkB) activation by
bacterial peptidoglycan and muramyl
dipeptide (MDP). MDP induced activa-
tion of NFkB in mononuclear cells is
absent in patients with Crohn’s disease
homozygous for the Leu1007fsinsC
mutation.27 28 It is therefore interesting
to speculate that NOD2 mutations asso-
ciated with Crohn’s disease result in
defective sensing of some bacteria
which may precipitate inappropriate
diffuse activation of NFkB and inflam-
mation through non-NOD2 mechan-
isms. Repeating the experiments with
Crohn’s mucosal explants13 from
patients with homozygous, heterozy-
gous, and double heterozygous NOD2
mutations, and appropriate controls
cocultured with Lactobacilli, may provide
interesting data using TNF readouts.
Our attempts to understand how
bacteria modulate the immune system
will undoubtedly yield novel therapeu-
tic targets and therapeutic agents.
Irrespective of whether or not dysbiosis
is reproducibly confirmed in IBD, we
need to consider probiotic therapy in
terms of specific molecules modulating
defined targets in the gut mucosal and
systemic immune system, and move
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Figure 1 Pathogen associated molecular
patterns (PAMPs) derived from bacteria
(including probiotics) are recognised by pattern
recognition receptors (PRRs, such as Toll-like
receptors). Initiation of dendritic cell (DC)
maturation starts after ligation of PRRs, which
also requires adaptor proteins such as MyD88
for signalling. Type of PAMPs determines the
selective priming of DCs for production of TH1,
TH2, and TReg lymphocyte polarising factors.
Different PAMPs ligate to specific
corresponding PRRs. IL, interleukin; TNF,
tumour necrosis factor; TGF-b, transforming
growth factor b.
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away from a simplistic concept of re-
populating the intestinal flora with
‘‘friendly’’ bacteria. Bacteria are only
‘‘friendly’’ in the context of the desired
immune modulation required for a
specific disease. The environment to
which the immune system is exposed
to determines DC phenotype and state
of activation and eventually drives the
balance between effector and regulatory
T cells (fig 1). Understanding probiotic
action may permit modulation of the
immune system, both locally and sys-
temically. The article by Sheil and
colleagues12 is the right step towards
stimulating further research where
immunologists, microbiologists, and
gastroenterologists can collaborate.
Gut 2004;53:620–622.
doi: 10.1136/gut.2003.034249
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Broadening our understanding of the role of matrix
metalloproteinases in Crohn’s disease
F
istulae are a common complication
of Crohn’s disease (CD), and their
most common perianal manifesta-
tion is present in 14–38% of CD patients
in referral populations.1 Despite
advances in conservative treatment,
fistulae rarely heal, while surgical resec-
tion is effective but frequently does not
prevent local recurrence or fistulising
disease at other sites.1 Remodelling of
the extracellular matrix (ECM) is a key
event in chronic bowel inflammation,2 3
especially in CD which is characterised
by both active fibrogenesis (that is, ECM
production and deposition), leading, for
example, to stricture formation, and by
enhanced fibrolyis (that is, breakdown
and removal of ECM), such as occurs in
fistula formation. While fibroblasts and
myofibroblasts, and to a minor degree
endothelial and epithelial cells, produce
the intestinal ECM, many more cell
types are involved in ECM breakdown
by releasing a broad spectrum of
enzymes that can degrade essentially
every ECM component, such as the
various collagens, non-collagenous
(glyco-) proteins, glycosaminoglycans,
and proteoglycans. The most important
of these enzymes are the matrix metal-
loproteinases (MMPs), a structurally
related class of at least 20 zinc depen-
dent proteases.4 5 MMPs are classified
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according to their primary specificities
and structural features into interstitial
collagenases (MMP-1, MMP-8, MMP-
13, MMP-18), gelatinases (degrading
denatured and basement membrane
collagens: MMP-2, MMP-9), stromely-
sins (degrading a broad spectrum of
ECM substrates: MMP-3, MMP-7,
MMP-10, MMP-11), elastases (MMP-
12), and membrane-type (transmem-
brane) MMPs (with broad substrate
specificities: MMP-14, MMP-15, MMP-
16, MMP-17, MMP-24, MMP-25).
As uncontrolled MMP activity would
virtually lead to dissolution of organs,
MMP activity is strictly controlled, not
only at the transcriptional and transla-
tional levels, but also by the require-
ment of proteolytic activation of the
zymogens and by several protease inhi-
bitors. Proteolytic activation occurs by
the plasminogen activator-plasmin cas-
cade and by certain active MMPs them-
selves, such as MMP-3, MMP-10, MMP-
14, and MMP-24. The most important
physiological inhibitors are the tissue
inhibitors of metalloproteinases (TIMP),
mainly TIMP-1, which blocks almost all
MMPs, and TIMP-2, which is specific
for MMP-2. A fifth level of control is
localisation of secreted MMPs either at
cell membrane compartments that are
involved in local ECM proteolysis (for
example, by binding to ECM receptors
that mediate cellular locomotion
through the matrix6 7) or on certain
ECM components, such as collagens.
Interestingly, it is preferentially the
inactive proforms of MMPs that bind
to collagen which become released from
the ECM on proteolytic activation.8 9
This illustrates that both homeostasis
and proteolytic remodelling of the ECM
are highly sophisticated and tightly
regulated processes, and that simply
measuring upregulation or downregula-
tion of MMPs and their inhibitors will
give a very incomplete picture of ECM
remodelling at best. In this line, no
characteristic difference is found
between procollagen mRNA levels as a
measure of fibrogenesis2 and MMP and
TIMP mRNA levels as a measure of
fibrolysis10–12 in inflamed colonic speci-
mens from patients with CD and ulcera-
tive colitis. This was initially unexpected
as CD often leads to stenosis due to
excess ECM deposition while fibrosis is
uncommon in ulcerative colitis. But it
comes as no surprise when one con-
siders the complex regulation of fibro-
lysis in the transmural inflammation of
CD.
The paper by Kirkegaard and collea-
gues13 in this issue of Gut brings our
understanding of the role of MMPs in
CD a step further [see page 701]. Using
complementary techniques, they identi-
fied and investigated MMP-3 and
MMP-9 as key players in fistulae of CD
and other causes. At first glance the
occurrence of fistulae, a manifestation
of enhanced fibrolytic activity, in a
fibrostenotic intestinal disease may
appear paradoxical. However, severe
inflammation which always leads to
release and activation of MMPs by cells
of the inflammatory infiltrate can drive
both processes: fistulae will form when
there is no rapid compensatory fibro-
genic response to fill up the defect,
perhaps favoured by a too quick re-
epithelialisation or re-endothelialisa-
tion; fibrosis will develop when the
fibrogenic response is strong and quick,
leading to scar formation. Both pro-
cesses can obviously coexist in close
proximity. What are the factors deter-
mining these divergent pathways?
Recent studies demonstrated that at
least early activation of MMPs is neces-
sary to allow for a fibrogenic
response,14 15 either by destroying base-
ment membranes which have a role in
maintaining cellular quiescence and
differentiation in the gut16 with subse-
quent mesenchymal activation, or by
allowing mesenchymal cell migration
and proliferation by removal of con-
straining ECM.
Thus the cellular source and temporo-
spatial pattern of MMP release and
activation probably explain these diver-
gent pathologies. As mesenchymal cells
(fibroblasts, myofibroblasts, and to a
lesser extent endothelial cells) and
inflammatory cells (mainly macro-
phages, monocytes, and neutrophils)
are the major sources of MMPs and
TIMPs, there must be a differently tuned
interplay of these cells driving either
fistula or fibrosis. Kirkegaard et al
observed that acute fistulising inflam-
mation in CD and other aetiologies is
characterised by high expression of
MMP-3 and MMP-9 coupled with high
activity of MMP-2 and MMP-9 in
inflammatory cells, while in chronic
fistulae, MMP-9 almost disappeared
but MMP-3 expression was maintained,
with a shift to mesenchymal, mainly
myofibroblastic, cells.13 The finding that
TIMPs remained low in all fistula speci-
mens is of interest as TIMP-1 in
particular is a major determinant of
fibrogenesis, as exemplified in liver
fibrosis.17 Low expression of TIMP-1 is
also characteristic of osteoarthritis, the
hallmark of which is unopposed MMP
activation in the joint leading to
destruction of cartilage and bone, some-
what reminiscent of fistula formation in
the gut.18 Also, it is osteoarthritis that
has led to a novel concept of chronic
fibrolytic inflammation that is driven by
altered synovial fibroblasts, the equiva-
lent of which could be myofibroblasts in
chronic fistulising diseases. These fibro-
blasts/myofibroblasts can secrete atypi-
cal chemokines attracting fibrolytic
inflammatory cells on the one hand,
and have a fibrolytic and migratory
phenotype themselves on the other.19
MMP-3, which has a broad substrate
specificity and which acts as a proacti-
vator (in addition to plasmin), at least of
MMP-1, MMP-2, and MMP-9, has been
identified as a particularly aggressive
enzyme in intestinal inflammation3
which favours invasiveness.20 This does
not exclude an important contribution
by MMP-12, MMP-13, MMP-14, and
MMP-19 which are expressed in
inflamed intestine21 but were not con-
sidered in this study.
Can we derive therapeutic concepts
from this and related studies on intest-
inal inflammation? A drug that effec-
tively prevents emerging or eliminates
chronic fistulae would be most wel-
come. Anti-inflammatory, antibiotic,
and immunosuppressive approaches
can lead to long term fistula control or
even closure in 25–50% of patients,
roughly doubling the placebo response
which is unsatisfactory.1 Anti-tumour
necrosis factor a (TNF-a) strategies can
lead to good short term and occasionally
long term results in cases that are
refractory to these therapies but treat-
ment is costly and may have grave side
effects.1 None the less, this approach is
rational as TNF-a is a potent inducer of
MMP-3 in intestinal myofibroblasts.3
Based on this and other studies, four
novel strategies aimed at inhibiting
intestinal inflammation and remodel-
ling in inflammatory bowel disease in
general, or in fistulising CD in particu-
lar, merit further exploration. These are
the use of: (1) inhibitors of growth
factors or cytokines, such as epidermal
growth factor, hepatocyte growth factor,
insulin-like growth factor (IGF-I and
IGF-II), fibroblast growth factor (aFGF,
bFGF), interleukin 1, and stem cell
factor that induce MMPs in epithelial
and mesenchymal cells22; (2) synthetic
inhibitors of kinases that trigger MMP
production, especially p38 kinase23; (3)
synthetic MMP inhibitors that were
shown to ameliorate experimental coli-
tis in mice24; and (4) inhibitors of
integrins (that is, cellular receptors for
ECM proteins that can bind to and/or
induce certain MMPs).6 25–28 Inhibition
of growth factors/cytokines and kinases
always carries the risk of side effects
because of their importance in normal
tissue regeneration and of their ubiqui-
tous expression in other cells and
organs. Inhibition of MMPs appears
more promising, especially as the first
generation of broad spectrum inhibitors
which have multiple side effects are
becoming replaced by orally available
subtype specific agents.18 However, the
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necessity for cell-type specific targeting
(for example, to MMP-3 expressing
myofibroblasts of fistulae) remains an
unsolved problem. Therefore, it is attrac-
tive to target integrins that promote
MMP-expression as many of these
receptors are cell-type specific. Thus
MMP-1, MMP-2, and MMP-3, MMP-
14, MMP-1 and MMP-3, and MMP-9
are induced and activated by integrins
a2b1, a4b1, a6b1, and avb3, respec-
tively, which are predominantly found
on activated (myo-) fibroblasts.6 25–28
Such inhibitors have (in part) been
developed, and orally available agents
are in phase I and II clinical studies (for
example, for metastatic tumour dis-
ease).29 It remains to combine the most
promising of these agents, alone or in
combination, with established therapies
in preclinical and clinical studies, for our
patients with complicated inflammatory
bowel disease.
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The circulating peptide hepcidin is important in the normal
response to iron overload, the pathogenesis of
haemochromatosis, and possibly the anaemia of chronic disease
I
n health, the body content of iron is
maintained within fairly narrow lim-
its to provide sufficient iron for
synthesis of ferroproteins essential for
oxygen transport and catalysis yet avoid
the toxic effects of excess. Early experi-
ments provided tantalising evidence for
a humoral regulatory factor. Serum
obtained from iron repleted rats inhib-
ited iron absorption in normal rat
duodenum.1 For many years this puta-
tive factor remained elusive. However,
recent studies indicate that a peptide
hormone, hepcidin, may play a crucial
regulatory role in normal iron home-
ostasis, haemochromatosis, and the
anaemia of chronic disease.2
Hepcidin was identified not from
studies of iron homeostasis but from
investigation of novel antimicrobial
peptides in body fluids. Krause and
colleagues3 screened human blood ultra-
filtrate (a source of the antimicrobial
peptides defensins) for small cysteine
rich peptides. A 25 amino acid peptide
with a mass of 2.7 kDa was found,
containing a remarkable eight disul-
phide bonded cysteine residues. It
showed antimicrobial activity against
some bacteria and the yeast Saccha-
romyces cerevisiae. Quantitative reverse
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transcription-polymerase chain reaction
showed predominant expression in
liver. The peptide was called LEAP-1
(liver-expressed antimicrobial peptide).3
The cDNA sequence predicted an 84
amino acid pre-propeptide with two
cleavage sites. The first predicts cleavage
of the N terminal endoplasmic reticu-
lum targeting signal sequence (amino
acids 1–24). The second consensus
cleavage site for prohormone conver-
tases would yield the central prodomain
(amino acids 25259) plus the 25 amino
acid C terminal peptide (also called
hepcidin-25; amino acids 60–84). A
slightly truncated 20 amino acid peptide
was also found (hepcidin 20; amino
acids 65–84). Independently, Park and
colleagues4 isolated the same cysteine
rich peptide from human urine and
named it hepcidin, reflecting its hepatic
expression and bactericidal properties.
In addition to hepcidin-20 and hepci-
din-25, a minor 22 amino acid form was
found (hepcidin-22; amino acids 63–
84). The antimicrobial activity of urinary
hepcidin was inhibited by 100–150 mM
NaCl,4 similar to the normal range for
plasma sodium (,135–145 mM).
Whether circulating plasma hepcidin
plays a significant antimicrobial role in
vivo therefore remains unclear.
Experiments in mice have shown that
hepcidin plays a role in iron regulation.
Pigeon et al identified mouse liver
hepcidin mRNA because it was induced
by carbonyl iron overload.5 The mouse
has two hepcidin genes in tandem
(probably arising from a duplication
event), located adjacent to the upstream
stimulatory factor 2 (Usf2) transcription
factor gene.5 Mice that lack hepatic
hepcidin expression, due to targeted
disruption of the adjacent Usf2 gene,
developed predominant iron loading of
parenchymal cells of the liver and
pancreas with relative sparing of the
macrophage rich spleen.6 Similar pat-
terns of iron overload in Hfe knockout
and Usf2 (hepcidin deficient) knockout
mice suggested that hepcidin and Hfe
may function in the same regulatory
pathway. Hepcidin was proposed to be a
negative regulator (that is, ‘‘inhibitor’’)
of iron absorption in the duodenum and
of iron release from macrophages.6 This
was supported by demonstration that
transgenic mice constitutively expres-
sing liver hepcidin died within a few
hours of birth with decreased body iron
levels and severe microcytic hypochro-
mic anaemia.7
Further observations implicate hepci-
din in the anaemia of chronic disease.
This is the most common anaemia of
hospitalised patients, often associated
with infection, cancer, and autoimmune
diseases. There is a diminished res-
ponse of erythroid precursors to
erythropoietin, decreased survival of
erythrocytes, impaired iron absorption,
and retention of iron in macrophages.
The net effect would be to decrease the
iron available to erythroid precursor
cells.8 9 Two patients with severe iron
refractory anaemia associated with
hepatic adenoma showed spontaneous
resolution of anaemia after removal of
the tumour.9 The adenomatous tissue
expressed inappropriately high levels of
hepcidin mRNA. On the basis of these
observations, it was proposed that hep-
cidin may be important in the patho-
genesis of anaemia of chronic disease.9
Analysis of urinary hepcidin excretion
in patients with anaemia due to chro-
nic infection or severe inflammatory
disease provided some confirmatory
evidence of increased hepcidin levels
in response to inflammation in
humans.10 In these patients, hepcidin
excretion correlated with serum ferritin
concentration which, like hepcidin,
increases in response to both elevated
body iron stores and inflammation.
Interestingly, injection of erythropoie-
tin into mice was shown to decrease
dramatically liver hepcidin expression.
Therefore, the efficacy of erythropoietin
in non-renal anaemias such as cancer
and autoimmune diseases may result
from both stimulation of erythropoie-
sis and inhibition of hepcidin expres-
sion, leading to increased plasma iron
levels.11
Regulation of hepcidin expression has
been investigated in cultured cells.
Surprisingly, iron loading of primary
human hepatocytes with either ferric
ammonium citrate or diferric transferrin
decreased hepcidin mRNA levels.10 This
is in contrast with experiments in mice
in which dietary or parenteral iron
loading increased hepcidin mRNA
levels.5 This suggested that during iron
overload in the whole animal, a signal
from non-parenchymal cells may induce
hepatocytes to express hepcidin.10
Mouse liver hepcidin mRNA is induced
not only by iron overload but also by
treatment with bacterial lipopolysac-
charide, hinting that iron and inflam-
matory cytokines may have a common
signalling pathway.5 Hepcidin mRNA in
primary human hepatocytes was
induced either by medium conditioned
by monocytes exposed to lipopolysac-
charide or by interleukin 6 (IL-6).10 At
the level of regulation by transcription
factors, the promoters of human and
mouse hepcidin genes contain at least
one functional binding site for CCAAT/
enhancer binding protein a (C/EBPa), a
transcription factor highly expressed in
adult liver which appears to stimulate
hepcidin expression. Hepatocyte nuclear
factor 4a (HNF4a) appears to reduce
hepcidin expression.12
The medical importance of hepcidin is
emphasised by recent studies in human
iron overload. Homozygous mutations
of hepcidin have been demonstrated in
two families with juvenile haemochro-
matosis.13 This disorder is characterised
by a rapid rate of iron loading, usually
causing presentation before the age of
30 years. There is a high frequency of
endocrine and cardiac iron overload,
and failure of early diagnosis and treat-
ment may be fatal.14 Juvenile haemo-
chromatosis is genetically hetero-
geneous with a second form mapping
to chromosome 1q21. Whether this
second gene will encode another protein
in the hepcidin-HFE pathway remains
to be resolved.15 The potential interac-
tion between hepcidin and HFE has also
been suggested by the description of
haemochromatosis associated with one
mutated allele of both hepcidin and
HFE, termed ‘‘digenic inheritance’’.16
The classical HFE related form of the
disease accounts for more than 90% of
well characterised haemochromatosis
patients in the UK.17 In HFE related
haemochromatosis and in Hfe knockout
mice, there is failure to upregulate
hepcidin levels despite hepatic iron
overload. This indicates that the HFE
protein is involved in regulation of hep-
cidin levels in response to iron. Disrup-
tion of the normal hepcidin response to
body iron stores may contribute to the
pathogenesis of iron overload seen in
HFE related haemochromatosis.18–20
Recognition of liver produced hepci-
din as an iron regulatory factor has
challenged the hypothesis that the con-
trol of iron absorption in relation to
body stores is mediated in duodenal
crypts. Hepcidin has revived the concept
that some regulation may be mediated
by the liver. Rats switched from a
control to an iron deficient diet showed
changes in hepcidin expression in close
temporal relationship with changes in
duodenal iron transporter expression.
This suggested that hepcidin may act
directly on villus enterocytes, pointing
to the liver as a regulatory site.21
Certainly, siderosis in Kupffer cells,
often on a background of mild iron
deposition in hepatocytes, is a familiar
feature of common liver diseases such as
hepatitis C infection and alcoholic liver
disease.22 Whether increased concentra-
tion of hepcidin, perhaps in response to
inflammation, has a role in the hepatic
siderosis observed in viral and alcoholic
liver disease remains to be demon-
strated.
To date, investigation of hepcidin in
various clinical conditions has been
impeded by the lack of anti-hepcidin
antibodies and suitable assays. Recently,
a western blot densitometric assay was
reported using an antibody raised
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against hepcidin-25, allowing quantita-
tion of human hepcidin in serum
samples.23 In this issue of Gut, Kulaksiz
and colleagues24 describe antisera raised
against two unique synthetic peptides
corresponding to the predicted human
hepcidin prodomain (two antisera to the
same peptide) and the mature hepcidin
C terminal peptide [see page 735]. All
three antisera detected immunoreactive
bands estimated at 10 and 20 kDa on
western blots of guinea pig and human
liver and HepG2 cells. The 10 kDa band
only was detected faintly in human
serum. Immunohistochemistry of
guinea pig and human liver with all
three antisera showed staining in hepa-
tocytes with a basolateral expression
pattern. This confirms and extends ear-
lier mRNA results, and is consistent
with basolateral release of hepcidin into
the liver sinusoids.24
A new enzyme linked immunosorbent
assay (ELISA) was developed using the
prodomain antiserum. The ELISA was
used to investigate serum levels of pro-
hepcidin immunoreactivity in controls
and patients with haemochromatosis,
renal anaemia, and chronic renal insuf-
ficiency. The mean level of pro-hepcidin
immunoreactivity detected in the serum
of healthy volunteers was an order of
magnitude greater than levels of hepci-
din detected in human urine.4 Pro-
hepcidin immunoreactivity was
increased in chronic renal insufficiency
patients who had normal haemoglobin
levels compared with the healthy con-
trol group, despite erythropoietin treat-
ment, which has been observed to
decrease hepatic hepcidin expression.11
These observations are therefore consis-
tent with renal metabolism and/or
elimination of peptide. Pro-hepcidin
was decreased in HFE related haemo-
chromatosis patients (C282Y homozy-
gous) compared with healthy controls,24
consistent with earlier mRNA studies,18
and indicating defective hepcidin regu-
lation in HFE related haemochromato-
sis.
Questions and inconsistencies remain
regarding the size and identity of
hepcidin immunoreactive bands on wes-
tern blots. The sequence of hepcidin-25
predicts a mass of 2.7 kDa, correspond-
ing to the result determined by mass
spectrometry.3 Furthermore, the oxi-
dised synthetic hepcidin-25 co-migrates
with native hepcidin-25 in analytical
high pressure liquid chromatography
and capillary electrophoresis.25 On wes-
tern blots however, serum hepcidin-25
immunoreactivity has been detected
with an apparent mass of 10 kDa, co-
migrating with the synthetic peptide,23
possibly reflecting aggregation of hepci-
din monomers.26 Kulaksiz et al detected
bands of 10 kDa and 20 kDa with their
three antisera on western blots.24 They
attributed the 10 kDa band to pro-
hepcidin on the grounds that it was
detected by antisera to both the mature
hepcidin peptide and to the prodo-
main. However, the predicted mass
of pro-hepcidin is 6.9 kDa; that of
pre-pro-hepcidin is 9.4 kDa (ExPASy
programme: http://ca.expasy.org/tools/
peptide-mass.html).27 It might be infor-
mative to compare the mobility of
synthetic peptides versus the bands
observed in human serum in this sys-
tem.24 Perhaps attention to denatura-
tion conditions and accurate verification
of experimentally determined mole-
cular masses may help to clarify the
discrepancies.
Is pro-hepcidin an active player in
iron regulation or merely a precursor
and an indirect measure of hepcidin
potential? Interestingly, a homozygous
point mutation of the human hepcidin
prodomain has been detected, predict-
ing a threonine to methionine substitu-
tion at amino acid 31 (T31M). This
individual had normal serum iron
indices, normal haemoglobin, and nor-
mal mean corpuscular volume.28
However, this residue is not conserved
in evolution: both wild-type mouse
hepcidin genes have a methionine at
the position equivalent to human threo-
nine 31. The normal phenotype asso-
ciated with homozygous T31M mutation
therefore does not resolve the role of
pro-hepcidin.
In summary, hepcidin is a peptide
hormone with important biological
effects on iron metabolism. It has
sequence homology to antimicrobial
peptides, although whether this func-
tion is conserved in vivo remains to be
demonstrated. Hepcidin is derived by
cleavage of a pre-propeptide; questions
remain about the processing and
activity of the peptide products. It has
been implicated as a regulator of body
iron stores and mutations have been
found in some families with juvenile
haemochromatosis. Iron balance is
probably sensed by Kupffer cells and
signalled to hepatocytes by cytokines
such as IL-6. Hepcidin expression is
also induced by inflammatory agents
giving it a potential role in the anaemia
of chronic disease. The reagents and
assays described24 will permit investiga-
tions of the role of hepcidin in clinical
samples in relation to the siderosis
observed in viral and alcoholic liver
diseases. This peptide is a fascinating
addition to the family of molecules
involved in iron metabolism. Future
studies of its action and regulation in
vivo and in vitro should fill in some
of the tantalising gaps in our under-
standing of this increasingly complex
field.
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Which gastrointestinal symptoms are useful in distinguishing
organic from functional disease?
P
atients and clinicians are becoming
increasingly intolerant of diagnostic
uncertainty. This is reflected in the
rising demand for endoscopic proce-
dures1 implicitly suggesting that gastro-
intestinal symptoms are an unreliable
indicator of serious pathology.
Unfortunately, the growing array of
tests that are being demanded for
patients are placing further pressures
on already stretched health care bud-
gets. The natural reaction to this is to
evaluate whether we can improve on the
value of the history to diagnose gastro-
intestinal disease. This process was
started over 30 years ago when
researchers such as Card and collea-
gues2 3 and de Dombal and colleagues4 5
evaluated the use of computers to aid
the clinician in making diagnoses in
patients with upper gastrointestinal
symptoms. The enthusiasm for this
approach faded when data suggested
that computer improved diagnostic
accuracy of computers was not suffi-
cient to prevent investigations.6 The
paucity of subsequent research in this
field is disappointing as it would be
useful to know what information com-
puters were using that enhanced diag-
nostic acumen. The article by Hammer
and colleagues7 in this issue of Gut [see
page 666] is therefore refreshing as it
prospectively evaluates a wide range of
gastrointestinal symptoms to establish
which are useful in distinguishing
organic from functional disease. The
strength of this study is that it evaluates
a large relatively unselected group of
patients, reducing spectrum and selec-
tion bias.8 It also divided patients into
those with and without organic disease
rather than subdividing the data into
different diagnoses. This improves the
power of the study and gives the
clinician overall information on whether
the patient is likely to have an organic
disease.
Their data suggest that aspects of the
history are valuable diagnostic tools for
lower gastrointestinal disease. They
identify three ‘‘alarm features’’ that
were important independent predictors
of organic lower gastrointestinal pathol-
ogy. These were age over 50 years, male
sex, and blood on the toilet paper. They
also identified five ‘‘non-alarm’’ fea-
tures (frequent abdominal pain, radiat-
ing pain, pain with loose bowel
movements, reflux, and absence of
diarrhoea) that independently predicted
functional bowel disease. The approach
of positively diagnosing functional
bowel disease with non-alarm symp-
toms or positively diagnosing organic
disease with alarm symptoms per-
formed equally well. The interesting
observation is that putting these two
pieces of information together improved
the accuracy of the model. This is
intuitive, as a clinician is likely to weigh
up the absence of alarm symptoms and
the presence of positive features indicat-
ing a functional bowel disorder before
deciding that the patient is at low risk of
significant organic disease.
These data will provide useful infor-
mation for the Rome group9 when they
next consider guidelines for the assess-
ment of irritable bowel syndrome (IBS).
They have highlighted symptoms simi-
lar to the classical Manning criteria that
are important in making a positive
diagnosis of functional gastrointestinal
disease but also other characteristics
such as radiating and frequent pain that
make IBS more likely. Unfortunately,
the model is probably not sufficiently
accurate to be used to exclude patients
from investigation in clinical practice.
Using the prevalence of lower gastro-
intestinal organic disease in the article,
the model had a positive predictive
value of 79% and a negative predictive
value of 86%. The possibility of missing
organic pathology in 14% of patients
would lead most clinicians to opt for
investigating even if the model pre-
dicted a low probability of disease. The
accuracy of the model may have been
improved if non-gastrointestinal symp-
toms such as backache and frequency of
micturition had been included10 but the
concern about using models to predict
organic disease is emphasised by the
conflicting messages from other studies.
For example, three papers also found
that rectal bleeding11–13 predicted organic
disease whereas two studies14 15 found
no statistically significant association.
Hammer et al found that weight loss and
anorexia were not independent predic-
tors of disease whereas others13 15 16
reported these symptoms were asso-
ciated with organic pathology. Finally,
Hammer and colleagues7 found that
severe abdominal pain was associated
with a reduced risk of having organic
pathology in the univariate analysis.
This observation is supported by one
study12 whereas another suggested
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abdominal pain is associated with colo-
rectal disease.17
These inconsistent findings probably
relate to differences in the design and
populations of the different studies. The
quality of the data collection on gastro-
intestinal symptoms, sample size, and
prevalence of underlying organic disease
varied between studies. In particular,
Hammer et al had very few colorectal
cancers in their sample and the main
organic disease driving the model was
inflammatory bowel disease. If ulcera-
tive colitis was the main disease found,
then rectal bleeding and absence of pain
will predict pathology and weight loss
may not be an important feature in the
model. It is interesting that the study12
that also had few colorectal cancers
found similar results, whereas the
report17 that evaluated a larger number
of colorectal cancers found that features
such as weight loss and abdominal pain
were important. The case mix of disease
in the underlying population is likely to
have a large influence on the symptoms
that computers models will predict are
important.
Upper gastrointestinal symptoms are
a good example of this. Hammer et al
found that weight loss, dysphagia, age,
and sex were not predictors of organic
pathology whereas other researchers
have found these to be significantly
associated with the risk of upper gastro-
intestinal cancer.18 19 Indeed, it is almost
inconceivable that male sex and increas-
ing age would not be risk factors for
upper gastrointestinal malignancy given
what is known about the epidemiology
of these cancers.1 Hammer et al did not
find that these were important because
the majority of their patients had
gastro-oesophageal reflux and peptic
ulcer and these diseases were driving
the model. It is not surprising therefore
that heartburn symptoms and aspirin
use were found to predict pathology
whereas alarm symptoms did not.
Although alarm symptoms may be of
more value than is suggested by this
paper, the overall message is consistent
with other researchers. Factors that are
found to be predictive of functional or
organic disease are not very useful
clinically. The model used by Hammer
et al found it very difficult to distinguish
between groups and as most patients
had organic disease it generally
defaulted to assigning patients to the
disease group. Others have found the
same problem: individual factors may be
statistically significantly associated with
disease but when they are combined in a
model they generally perform very
poorly.20 This is particularly true when
the models are tested prospectively21 or
transferred from a hospital to a primary
care setting.22
Science has a great deal to offer the
clinician in helping determine a diag-
nosis from the patient history.
Statistical techniques can identify symp-
toms and signs that are important to
consider and those that do not contri-
bute to making a diagnosis. The problem
is that a single study is not sufficient.
After all, we do not rely on one study to
definitively tell us that smoking causes
lung cancer or Helicobacter pylori causes
distal gastric adenocarcinoma. There is a
need for a range of diagnostic studies
conducted in different settings using
different designs. The common feature
of all should be the careful prospective
collection of a detailed symptom assess-
ment.23 When sufficient data have been
accumulated, a picture will emerge on
what are the important features that
identify a patients as having organic
disease. The problem that is addressed
also has to be amenable to this
approach. It will be difficult to use the
history to guide us in patients with
upper gastrointestinal disease but the
situation with lower gastrointestinal
pathology looks more promising.
Insights provided by diagnostic studies
may allow us to avoid invasive tests
in some patients and identify others
as having a high risk of serious
colorectal disease that warrants urgent
investigation. It is not sufficient to show
the sensitivity and specificity of this
approach as the ultimate goal is to
provide more cost effective health care
to patients.24 Randomised controlled
trials will therefore be required to assess
whether a more thorough clinical his-
tory will reduce costs or improve patient
outcomes.
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